DK0858343T3
(da)
|
1995-11-02 |
2004-05-10 |
Schering Corp |
Kontinuerlig lavdosis cytokininfusionsterapi
|
US5908621A
(en)
*
|
1995-11-02 |
1999-06-01 |
Schering Corporation |
Polyethylene glycol modified interferon therapy
|
US20030190307A1
(en)
|
1996-12-24 |
2003-10-09 |
Biogen, Inc. |
Stable liquid interferon formulations
|
WO1999003887A1
(en)
*
|
1997-07-14 |
1999-01-28 |
Bolder Biotechnology, Inc. |
Derivatives of growth hormone and related proteins
|
US20080076706A1
(en)
|
1997-07-14 |
2008-03-27 |
Bolder Biotechnology, Inc. |
Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
|
US6753165B1
(en)
*
|
1999-01-14 |
2004-06-22 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
US7270809B2
(en)
*
|
1997-07-14 |
2007-09-18 |
Bolder Biotechnology, Inc. |
Cysteine variants of alpha interferon-2
|
KR100364938B1
(ko)
*
|
1997-09-18 |
2002-12-18 |
에프. 호프만-라 로슈 아게 |
만성 씨형 간염의 치료를 위한 인테페론-알파와 아만타딘을 함유한 약제
|
US6172046B1
(en)
*
|
1997-09-21 |
2001-01-09 |
Schering Corporation |
Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
|
IL138221A0
(en)
*
|
1998-03-26 |
2001-10-31 |
Schering Corp |
Formulations for protection of peg-interferon alpha conjugates
|
US6180096B1
(en)
|
1998-03-26 |
2001-01-30 |
Schering Corporation |
Formulations for protection of peg-interferon alpha conjugates
|
EP1213029A1
(en)
*
|
1998-05-15 |
2002-06-12 |
Schering Corporation |
Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
|
ITMI981148A1
(it)
*
|
1998-05-22 |
1999-11-22 |
Therapicon Srl |
Utilizzo di lisozima c modificato per preparare composizioni medicinali per il trattamento di alcune gravi malattie
|
CA2334267C
(en)
*
|
1998-06-08 |
2009-02-17 |
F. Hoffmann-La Roche Ag |
Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
|
EP1113794A2
(en)
*
|
1998-09-14 |
2001-07-11 |
Vertex Pharmaceuticals Incorporated |
Methods of treating viral disease
|
EP2599503B1
(en)
|
1998-10-16 |
2017-05-17 |
Biogen MA Inc. |
Polymer conjugates of interferon beta-1A and uses thereof
|
PT1121382E
(pt)
|
1998-10-16 |
2006-10-31 |
Biogen Idec Inc |
Proteinas de fusao do interferao beta e as respectivas utilizacoes
|
CA2354536A1
(en)
*
|
1998-12-18 |
2000-06-29 |
Schering Corporation |
Ribavirin-pegylated interferon alfa induction hcv combination therapy
|
US8288126B2
(en)
|
1999-01-14 |
2012-10-16 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
WO2000051631A2
(en)
*
|
1999-03-02 |
2000-09-08 |
Schering Corporation |
Pegylated alpha interferon for hiv therapy
|
TWI292320B
(en)
*
|
1999-04-08 |
2008-01-11 |
Schering Corp |
Melanoma therapy
|
AR029160A1
(es)
*
|
1999-04-08 |
2003-06-18 |
Schering Corp |
El uso del interferon-alfa pegilado para la preparacion de un medicamento para el tratamiento del carcinoma de celula renal, un kit y el uso del mismo
|
US6362162B1
(en)
|
1999-04-08 |
2002-03-26 |
Schering Corporation |
CML Therapy
|
US6605273B2
(en)
|
1999-04-08 |
2003-08-12 |
Schering Corporation |
Renal cell carcinoma treatment
|
AR023390A1
(es)
*
|
1999-04-08 |
2002-09-04 |
Schering Corp |
Terapia para la leucemia mielocitica cronica
|
US6923966B2
(en)
|
1999-04-08 |
2005-08-02 |
Schering Corporation |
Melanoma therapy
|
US6635646B1
(en)
*
|
1999-05-04 |
2003-10-21 |
Schering Corporation |
Pegylated interferon alfa-CCR5 antagonist combination HIV therapy
|
WO2000066141A2
(en)
*
|
1999-05-04 |
2000-11-09 |
Schering Corporation |
Pegylated interferon alfa-ccr5 antagonist combination hiv therapy
|
JP2003507339A
(ja)
*
|
1999-08-13 |
2003-02-25 |
エフ.ホフマン−ラ ロシュ アーゲー |
PEG−IFN−αと共同させたミコフェノラートモフェチル
|
JP2003510281A
(ja)
*
|
1999-09-29 |
2003-03-18 |
ザ クリーブランド クリニック ファウンデーション |
2−5aおよびインターフェロンを用いる治療
|
JP2001288109A
(ja)
*
|
2000-04-06 |
2001-10-16 |
Schering Plough Corp |
黒色腫治療
|
MY164523A
(en)
*
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
EA007867B1
(ru)
*
|
2000-05-26 |
2007-02-27 |
Айденикс (Кайман) Лимитед |
Композиции для лечения флавивирусных и пестивирусных инфекций и способы их применения
|
US7208167B2
(en)
*
|
2000-08-07 |
2007-04-24 |
Sciclone Pharmaceuticals, Inc. |
Treatment of hepatitis C with thymosin and peptide combination therapy
|
CA2418154A1
(en)
*
|
2000-08-07 |
2002-02-14 |
Sciclone Pharmaceuticals, Inc. |
Treatment of hepatitis c with thymosin and pegylated interferon
|
WO2002026265A2
(en)
*
|
2000-09-29 |
2002-04-04 |
Schering Corporation |
Pegylated interleukin-10
|
EP1450836A4
(en)
*
|
2000-11-03 |
2007-07-25 |
Intarcia Therapeutics Inc |
PROCESS FOR SHORT AND LONG-TERM DOSAGE OF MEDICAMENTS
|
WO2002044717A1
(en)
*
|
2000-12-01 |
2002-06-06 |
Cornell Research Foundation |
Animal model for flaviviridae infection
|
CA2429769C
(en)
*
|
2000-12-07 |
2016-04-26 |
Board Of Regents, The University Of Texas System |
Methods of treatment involving human mda-7
|
US6720000B2
(en)
|
2001-03-19 |
2004-04-13 |
Three Rivers Pharmaceutical, Llc |
Process for producing wet ribavirin pellets
|
WO2003026589A2
(en)
*
|
2001-09-28 |
2003-04-03 |
Idenix (Cayman) Limited |
Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
|
CN1738635A
(zh)
*
|
2001-10-05 |
2006-02-22 |
印特缪恩股份有限公司 |
用多阶段干扰素传递曲线治疗肝炎病毒感染的方法
|
UA78726C2
(en)
*
|
2001-11-01 |
2007-04-25 |
Sciclone Pharmaceuticals Inc |
Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment
|
MXPA04004181A
(es)
*
|
2001-11-02 |
2005-01-25 |
Sandoz Ag |
Procedimiento para preparar composiciones de ribavirina de alta carga, de rapida disolucion.
|
US20030143197A1
(en)
*
|
2001-11-09 |
2003-07-31 |
Moran S. Mark |
Method for treating diseases with omega interferon
|
KR100480429B1
(ko)
*
|
2001-12-04 |
2005-04-06 |
선바이오(주) |
인터페론-알파와 폴리에틸렌글리콜 유도체의 배합체
|
AU2002346686A1
(en)
*
|
2001-12-07 |
2003-06-23 |
Intermune, Inc. |
Compositions and method for treating hepatitis virus infection
|
RS55578B1
(sr)
|
2002-01-18 |
2017-06-30 |
Biogen Ma Inc |
Polimerna jedinjenja polialkilena i njihova upotreba
|
AU2003217402A1
(en)
*
|
2002-02-14 |
2003-09-04 |
Pharmasset Inc |
Modified fluorinated nucleoside analogues
|
US20040009939A1
(en)
*
|
2002-03-05 |
2004-01-15 |
Board Of Regent, The University Of Texas System |
Methods of enhancing immune induction involving MDA-7
|
US20040034206A1
(en)
*
|
2002-05-31 |
2004-02-19 |
Schering Corporation |
Combination therapy for RNA virus infections involving ribavirin and IMPDH inhibitors
|
CN103319554A
(zh)
|
2002-06-28 |
2013-09-25 |
埃迪尼克斯医药公司 |
用于治疗黄病毒感染的修饰的2’和3’-核苷前药
|
US7608600B2
(en)
|
2002-06-28 |
2009-10-27 |
Idenix Pharmaceuticals, Inc. |
Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
|
AP2005003213A0
(en)
*
|
2002-06-28 |
2005-03-31 |
Univ Cagliari |
2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections.
|
CN101172993A
(zh)
*
|
2002-06-28 |
2008-05-07 |
埃迪尼克斯(开曼)有限公司 |
用于治疗黄病毒感染的2′-c-甲基-3′-o-l-缬氨酸酯核糖呋喃基胞苷
|
KR20040020817A
(ko)
|
2002-08-31 |
2004-03-09 |
씨제이 주식회사 |
당쇄화된 사람 인터페론 알파 동종체
|
US7538094B2
(en)
*
|
2002-09-19 |
2009-05-26 |
Three Rivers Pharmacueticals, Llc |
Composition containing ribavirin and use thereof
|
AU2003295395A1
(en)
*
|
2002-11-04 |
2004-06-07 |
4Life Research, Lc |
Compositions, systems, and methods for focusing a cell-mediated immune response
|
US7824851B2
(en)
|
2002-11-15 |
2010-11-02 |
Idenix Pharmaceuticals, Inc. |
2′-branched nucleosides and Flaviviridae mutation
|
JP4206382B2
(ja)
*
|
2002-11-19 |
2009-01-07 |
アキリオン ファーマシューティカルズ,インコーポレーテッド |
置換されたアリールチオウレアおよび関連化合物;ウイルス複製のインヒビター
|
CN100501400C
(zh)
|
2002-11-25 |
2009-06-17 |
希克龙制药公司 |
使用α胸腺素防护辐射损伤的方法
|
CA2509687C
(en)
*
|
2002-12-12 |
2012-08-14 |
Idenix (Cayman) Limited |
Process for the production of 2'-branched nucleosides
|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
GB0301879D0
(en)
*
|
2003-01-27 |
2003-02-26 |
Regent Res Llp |
HCV combination therapy
|
WO2004078127A2
(en)
*
|
2003-02-28 |
2004-09-16 |
Intermune, Inc. |
Continuous delivery methods for treating hepatitis virus infection
|
AU2003225670A1
(en)
*
|
2003-02-28 |
2004-09-28 |
Intermune, Inc. |
Interferon drug therapy for the treatment of viral diseases and liver fibrosis
|
AU2004218407A1
(en)
*
|
2003-03-03 |
2004-09-16 |
Board Of Regents, The University Of Texas System |
Methods and compositions involving MDA-7
|
WO2004093901A1
(en)
*
|
2003-03-28 |
2004-11-04 |
Intermune, Inc. |
Compositions and methods for treating poxvirus infection
|
US20100311656A1
(en)
*
|
2003-04-23 |
2010-12-09 |
Sciclone Pharmaceuticals, Inc. |
Treatment or prevention of respiratory viral infections with alpha thymosin peptides
|
EP2345659A1
(en)
|
2003-05-30 |
2011-07-20 |
Pharmasset, Inc. |
Modified fluorinated nucleoside analogues
|
GB0320638D0
(en)
|
2003-09-03 |
2003-10-01 |
Novartis Ag |
Organic compounds
|
WO2005037214A2
(en)
|
2003-10-14 |
2005-04-28 |
Intermune, Inc. |
Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
|
WO2005082396A2
(en)
*
|
2003-12-01 |
2005-09-09 |
Introgen Therapeutics, Inc. |
Use of mda-7 to inhibit infection by pathogenic organisms
|
GB0500020D0
(en)
|
2005-01-04 |
2005-02-09 |
Novartis Ag |
Organic compounds
|
US8778880B2
(en)
|
2004-02-02 |
2014-07-15 |
Ambrx, Inc. |
Human growth hormone modified at position 35
|
AU2008201682B2
(en)
*
|
2004-02-02 |
2011-02-24 |
Ambrx, Inc. |
Modified human interferon polypeptides and their uses
|
CN100355784C
(zh)
*
|
2004-02-12 |
2007-12-19 |
江苏恒瑞医药股份有限公司 |
聚乙二醇修饰α-干扰素1b的制备方法
|
US20070281041A1
(en)
*
|
2004-03-02 |
2007-12-06 |
Introgen Therapeutics, Inc. |
Compositions and Methods Involving MDA-7 for the Treatment of Cancer
|
CN1980657A
(zh)
|
2004-05-05 |
2007-06-13 |
耶鲁大学 |
新颖的抗病毒赛菊宁黄质类似物
|
CN1964731A
(zh)
*
|
2004-05-14 |
2007-05-16 |
希克龙制药公司 |
用免疫调节剂化合物治疗或预防呼吸道病素性感染
|
ATE497775T1
(de)
*
|
2004-07-14 |
2011-02-15 |
Novartis Pharma Gmbh |
Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv)
|
CN101023094B
(zh)
*
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
BRPI0513332A
(pt)
|
2004-08-12 |
2008-05-06 |
Schering Corp |
formulação de interferon peguilado estável
|
EP1809301B1
(en)
*
|
2004-09-14 |
2019-11-06 |
Gilead Pharmasset LLC |
2-fluoro-2-alkyl-substituted d-ribonolactone intermediates
|
EP2899277A1
(en)
|
2004-11-26 |
2015-07-29 |
Pieris AG |
Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
|
AU2005322241B2
(en)
*
|
2004-12-23 |
2010-02-18 |
Novartis Ag |
Compounds for flaviviridae treatment
|
RU2007128099A
(ru)
*
|
2004-12-23 |
2009-01-27 |
Новартис АГ (CH) |
Композиции для лечения гепатита с
|
WO2006083761A2
(en)
|
2005-02-03 |
2006-08-10 |
Alza Corporation |
Solvent/polymer solutions as suspension vehicles
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
EP1863516A2
(en)
*
|
2005-02-08 |
2007-12-12 |
Board of Regents, The University of Texas System |
Compositions and methods involving mda-7 for the treatment of cancer
|
ES2302402B1
(es)
*
|
2005-06-16 |
2009-05-08 |
Proyecto De Biomedicina Cima, S.L. |
Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.
|
ATE524183T1
(de)
|
2005-06-17 |
2011-09-15 |
Novartis Ag |
Verwendung von sanglifehrin bei der hcv-therapie
|
US7695710B2
(en)
*
|
2005-06-20 |
2010-04-13 |
Pepgen Corporation |
Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
|
TW200722104A
(en)
*
|
2005-06-20 |
2007-06-16 |
Pepgen Corp |
Low-toxicity, long-circulating human interferon-α analogs
|
JP5249028B2
(ja)
|
2005-07-25 |
2013-07-31 |
インターミューン・インコーポレーテッド |
C型肝炎ウイルス複製の新規大環状阻害剤
|
DE602006019323D1
(de)
|
2005-10-11 |
2011-02-10 |
Intermune Inc |
Verbindungen und verfahren zur inhibierung der replikation des hepatitis-c-virus
|
CA2634749C
(en)
*
|
2005-12-23 |
2014-08-19 |
Idenix Pharmaceuticals, Inc. |
Process for preparing a synthetic intermediate for preparation of branched nucleosides
|
AU2007205545B9
(en)
|
2006-01-12 |
2012-10-18 |
Hokusan Co. Ltd. |
Oral composition containing interferon-alpha
|
WO2007126950A1
(en)
*
|
2006-03-31 |
2007-11-08 |
Schering Corporation |
Parenteral low dose type 1 interferons for bladder cancer
|
MX2008013119A
(es)
|
2006-04-11 |
2008-10-21 |
Novartis Ag |
Inhibidores de hcv/vih y sus usos.
|
MX2008014870A
(es)
|
2006-05-30 |
2009-02-12 |
Intarcia Therapeutics Inc |
Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
|
US8114150B2
(en)
*
|
2006-06-14 |
2012-02-14 |
Advanced Cardiovascular Systems, Inc. |
RGD peptide attached to bioabsorbable stents
|
AR078117A1
(es)
|
2006-06-20 |
2011-10-19 |
Protech Pharma S A |
Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina
|
JP2009545621A
(ja)
|
2006-08-02 |
2009-12-24 |
ユナイテッド セラピューティクス コーポレーション |
ウィルス感染症のリポソーム処置
|
EP2359808B1
(en)
|
2006-08-09 |
2013-05-22 |
Intarcia Therapeutics, Inc |
Osmotic delivery systems and piston assemblies
|
EP2054076A2
(en)
*
|
2006-08-21 |
2009-05-06 |
United Therapeutics Corporation |
Combination therapy for treatment of viral infections
|
US8679472B1
(en)
|
2006-10-05 |
2014-03-25 |
Merck, Sharp & Dohme Corp. |
Crystal of human interferon alpha 2B in complex with zinc
|
BRPI0719189A2
(pt)
*
|
2006-10-12 |
2018-08-14 |
Univ Kyushu Nat Univ Corp |
uso de ciclosporinas modificadas
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
CN105688191A
(zh)
|
2007-04-23 |
2016-06-22 |
精达制药公司 |
促胰岛素释放肽的混悬制剂及其应用
|
EP2076533B1
(en)
|
2007-05-02 |
2014-10-08 |
Ambrx, Inc. |
Modified interferon beta polypeptides and their uses
|
NZ602170A
(en)
|
2008-02-08 |
2014-03-28 |
Ambrx Inc |
Modified leptin polypeptides and their uses
|
WO2009102467A2
(en)
|
2008-02-13 |
2009-08-20 |
Intarcia Therapeutics, Inc. |
Devices, formulations, and methods for delivery of multiple beneficial agents
|
CA2719567A1
(en)
*
|
2008-03-26 |
2009-10-01 |
University Of Oxford |
Endoplasmic reticulum targeting liposomes
|
TW200946541A
(en)
*
|
2008-03-27 |
2009-11-16 |
Idenix Pharmaceuticals Inc |
Solid forms of an anti-HIV phosphoindole compound
|
EP2113256A1
(en)
|
2008-04-29 |
2009-11-04 |
Ascendis Pharma AS |
PEGylated rhGH compounds
|
DK2279007T3
(en)
|
2008-04-29 |
2016-08-22 |
Ascendis Pharma Growth Disorders Div As |
Pegylated recombinant relations of human growth hormone
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
WO2009156456A1
(en)
|
2008-06-24 |
2009-12-30 |
Technische Universität München |
Muteins of hngal and related proteins with affinity for a given target
|
EA019965B1
(ru)
*
|
2008-09-17 |
2014-07-30 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Комбинация ингибитора протеазы ns3 hcv с интерфероном и рибавирином
|
US8691205B2
(en)
|
2008-12-17 |
2014-04-08 |
Merck Sharp & Dohme Corporation |
Mono- and di-PEG IL-10 production; and uses
|
US8716262B2
(en)
|
2008-12-23 |
2014-05-06 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
SG194404A1
(en)
|
2008-12-23 |
2013-11-29 |
Gilead Pharmasset Llc |
Synthesis of purine nucleosides
|
US8551973B2
(en)
|
2008-12-23 |
2013-10-08 |
Gilead Pharmasset Llc |
Nucleoside analogs
|
US8623348B2
(en)
*
|
2009-03-27 |
2014-01-07 |
Jw Pharmaceutical Corporation |
Interferon-α (IFN-α) fused proteins comprising IFN-α and a cytoplasmic transduction peptide (CTP)
|
CN102427804A
(zh)
*
|
2009-03-27 |
2012-04-25 |
牛津大学之校长及学者 |
降低胆固醇水平的脂质体
|
US8512690B2
(en)
|
2009-04-10 |
2013-08-20 |
Novartis Ag |
Derivatised proline containing peptide compounds as protease inhibitors
|
US20110182850A1
(en)
|
2009-04-10 |
2011-07-28 |
Trixi Brandl |
Organic compounds and their uses
|
TWI576352B
(zh)
*
|
2009-05-20 |
2017-04-01 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
US20110027229A1
(en)
|
2009-07-31 |
2011-02-03 |
Medtronic, Inc. |
Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
|
CN106139123A
(zh)
|
2009-08-05 |
2016-11-23 |
爱力根公司 |
脂质运载蛋白突变蛋白的控制释放制剂
|
MX352878B
(es)
|
2009-09-28 |
2017-12-13 |
Intarcia Therapeutics Inc |
Establecimiento y/o terminacion rapidos de suministro de estado estable sustancial de farmaco.
|
AU2010313497B2
(en)
|
2009-10-30 |
2013-08-01 |
Boehringer Ingelheim International Gmbh |
Dosage regimens for HCV combination therapy comprising BI201335, interferon alpha and ribavirin
|
WO2011069992A2
(en)
|
2009-12-07 |
2011-06-16 |
Pieris Ag |
Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target
|
CN104017020B
(zh)
|
2010-03-31 |
2017-04-12 |
吉利德制药有限责任公司 |
核苷氨基磷酸酯
|
PL3290428T3
(pl)
|
2010-03-31 |
2022-02-07 |
Gilead Pharmasset Llc |
Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
|
PT2580236T
(pt)
|
2010-06-08 |
2019-05-30 |
Astrazeneca Ab |
Muteínas da lipocalina de lágrima, que se ligam ao recetor-alfa da il-4
|
WO2011159930A2
(en)
|
2010-06-16 |
2011-12-22 |
Medtronic, Inc. |
Damping systems for stabilizing medications in drug delivery devices
|
EP2585065A1
(en)
|
2010-06-24 |
2013-05-01 |
Panmed Ltd. |
Treatment of hepatitis c virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent
|
NZ606584A
(en)
|
2010-08-16 |
2014-10-31 |
Pieris Ag |
Binding proteins for hepcidin
|
WO2012045704A1
(en)
|
2010-10-05 |
2012-04-12 |
Novartis Ag |
New treatments of hepatitis c virus infection
|
KR20130120481A
(ko)
|
2010-10-08 |
2013-11-04 |
노파르티스 아게 |
술파미드 ns3 억제제의 비타민 e 제제
|
DK2640740T3
(en)
|
2010-11-15 |
2017-06-26 |
Pieris Pharmaceuticals Gmbh |
MUTEINS OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR GLYPICAN-3 (GPC3)
|
WO2012075140A1
(en)
|
2010-11-30 |
2012-06-07 |
Pharmasset, Inc. |
Compounds
|
CN103221053A
(zh)
|
2010-11-30 |
2013-07-24 |
诺华有限公司 |
丙型肝炎病毒感染的新疗法
|
EP2646552B1
(en)
|
2010-12-02 |
2017-07-05 |
Pieris Pharmaceuticals GmbH |
Muteins of human lipocalin 2 with affinity for ctla-4
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
CN103476409A
(zh)
|
2011-03-31 |
2013-12-25 |
诺华股份有限公司 |
治疗丙肝病毒感染的阿拉泊韦
|
CA2831675A1
(en)
|
2011-04-01 |
2012-10-04 |
Novartis Ag |
Treatment for infection with hepatitis b virus alone or in combination with hepatitis delta virus and associated liver diseases
|
AU2012241859A1
(en)
|
2011-04-13 |
2013-10-10 |
Debiopharm International Sa |
Treatment of Hepatitis C virus infection with alisporivir
|
RU2014116988A
(ru)
|
2011-09-27 |
2015-11-10 |
Новартис Аг |
Алиспоривир для лечения инфекции, вызванной вирусом гепатита с
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
EP3453400B1
(en)
|
2011-12-13 |
2021-01-20 |
Pieris Pharmaceuticals GmbH |
Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors
|
US8809354B2
(en)
|
2011-12-31 |
2014-08-19 |
Sheikh Riazuddin |
3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
|
JP2015509980A
(ja)
|
2012-03-14 |
2015-04-02 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Hcv−hiv同時感染患者集団のhcv感染症を治療するための併用療法
|
JP2015512900A
(ja)
|
2012-03-28 |
2015-04-30 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
特別な患者の遺伝子亜型分集団のhcv感染症を治療するための併用療法
|
US9522940B2
(en)
|
2012-05-23 |
2016-12-20 |
Pieris Pharmaceuticals Gmbh |
Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3
|
US10526384B2
(en)
|
2012-11-19 |
2020-01-07 |
Pieris Pharmaceuticals Gmbh |
Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereof
|
RU2015142437A
(ru)
|
2013-03-14 |
2017-04-27 |
Дайити Санкио Ко., Лтд |
Новые связывающие белки для pcsk9
|
RU2679889C2
(ru)
|
2013-04-18 |
2019-02-14 |
Армо Байосайенсиз, Инк. |
Способы применения интерлейкина-10 для лечения заболеваний и расстройств
|
EP3010527B1
(en)
|
2013-06-17 |
2018-08-08 |
Armo Biosciences, Inc. |
Method for assessing protein identity and stability
|
NZ716840A
(en)
|
2013-08-27 |
2017-06-30 |
Gilead Pharmasset Llc |
Combination formulation of two antiviral compounds
|
EP3038642A4
(en)
|
2013-08-30 |
2017-01-18 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
CA2928710A1
(en)
|
2013-11-11 |
2015-05-14 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
WO2015104406A2
(en)
|
2014-01-13 |
2015-07-16 |
Pieris Ag |
Multi-specific polypeptide useful for localized tumor immunomodulation
|
CN113621050A
(zh)
|
2014-05-22 |
2021-11-09 |
皮里斯制药有限公司 |
新型特异性结合多肽及其用途
|
CN106573072A
(zh)
|
2014-06-02 |
2017-04-19 |
阿尔莫生物科技股份有限公司 |
降低血清胆固醇的方法
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
JP2017536098A
(ja)
|
2014-10-14 |
2017-12-07 |
アルモ・バイオサイエンシーズ・インコーポレイテッド |
インターロイキン−15組成物及びその使用
|
EP3209320B1
(en)
|
2014-10-22 |
2023-03-08 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
MX2017009767A
(es)
|
2015-01-28 |
2018-08-15 |
Pieris Pharmaceuticals Gmbh |
Nuevas proteínas específicas para la angiogénesis.
|
US10618970B2
(en)
|
2015-02-03 |
2020-04-14 |
Armo Biosciences, Inc. |
Method of treating cancer with IL-10 and antibodies that induce ADCC
|
MX2017010628A
(es)
|
2015-02-18 |
2017-12-07 |
Sanofi Sa |
Proteinas especificas novedosas para pioverdina y pioquelina.
|
CA2980839A1
(en)
|
2015-05-04 |
2016-11-10 |
Pieris Pharmaceuticals Gmbh |
Proteins specific for cd137
|
CN114316067A
(zh)
|
2015-05-04 |
2022-04-12 |
皮里斯制药有限公司 |
抗癌融合多肽
|
CA2980838A1
(en)
|
2015-05-18 |
2016-11-24 |
Pieris Pharmaceuticals Gmbh |
Anti-cancer fusion polypeptide
|
CN114456252A
(zh)
|
2015-05-18 |
2022-05-10 |
皮里斯制药有限公司 |
对磷脂酰肌醇聚糖-3(gpc3)具有亲和力的人脂质运载蛋白2的突变蛋白
|
WO2016191587A1
(en)
|
2015-05-28 |
2016-12-01 |
Armo Biosciences, Inc. |
Pegylated interleukin-10 for use in treating cancer
|
JP6993235B2
(ja)
|
2015-06-03 |
2022-01-13 |
インターシア セラピューティクス,インコーポレイティド |
インプラントの設置及び撤去システム
|
EP3115371A1
(en)
|
2015-07-07 |
2017-01-11 |
Sanofi |
Fusion molecules
|
KR20180029238A
(ko)
|
2015-07-15 |
2018-03-20 |
피어이스 파마슈티컬즈 게엠베하 |
Lag-3에 특이적인 신규 단백질
|
AU2016312510A1
(en)
|
2015-08-25 |
2018-03-08 |
Armo Biosciences, Inc. |
Methods of using Interleukin-10 for treating diseases and disorders
|
EP3383921A4
(en)
|
2015-11-30 |
2019-04-17 |
Pieris Australia Pty Ltd. |
NOVEL ANTI-ANGIOGENIC FUSION POLYPEPTIDES
|
TW201725212A
(zh)
|
2015-12-10 |
2017-07-16 |
第一三共股份有限公司 |
特異性於降鈣素基因相關胜肽的新穎蛋白
|
EP3458084B1
(en)
|
2016-05-16 |
2020-04-01 |
Intarcia Therapeutics, Inc |
Glucagon-receptor selective polypeptides and methods of use thereof
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
JP7093311B2
(ja)
*
|
2016-06-20 |
2022-06-29 |
エランコ・ユーエス・インコーポレイテッド |
ペグ化ブタインターフェロンおよびその使用方法
|
US10919904B2
(en)
|
2016-08-17 |
2021-02-16 |
North Carolina State University |
Northern-southern route to synthesis of bacteriochlorins
|
WO2018087108A1
(en)
|
2016-11-09 |
2018-05-17 |
Pieris Pharmaceuticals Gmbh |
Proteins specific for cd137
|
US10836774B2
(en)
|
2016-11-30 |
2020-11-17 |
North Carolina State University |
Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
|
KR20190104039A
(ko)
|
2017-01-03 |
2019-09-05 |
인타르시아 세라퓨틱스 인코포레이티드 |
Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
|
CA3050194A1
(en)
|
2017-01-18 |
2018-07-26 |
Pieris Pharmaceuticals Gmbh |
Lipocalin muteins with binding affinity for lag-3
|
LT3830120T
(lt)
|
2018-07-31 |
2023-07-10 |
Pieris Pharmaceuticals Gmbh |
Naujas sulietas baltymas specifinis cd137 ir pd-l1 atžvilgiu
|
KR20210133254A
(ko)
|
2019-02-26 |
2021-11-05 |
피어이스 파마슈티컬즈 게엠베하 |
Cd137 및 gpc3에 특이적인 신규한 융합 단백질
|
EP4161957A1
(en)
|
2020-06-05 |
2023-04-12 |
Pieris Pharmaceuticals GmbH |
Multimeric immunomodulator targeting 4-1bb
|
CA3214220A1
(en)
|
2021-04-08 |
2022-10-13 |
Marina PAVLIDOU |
Novel lipocalin muteins specific for connective tissue growth factor (ctgf)
|
WO2022243341A1
(en)
|
2021-05-18 |
2022-11-24 |
Pieris Pharmaceuticals Gmbh |
Lipocalin muteins with binding affinity for ox40
|
WO2024064713A1
(en)
|
2022-09-21 |
2024-03-28 |
Seagen Inc. |
Novel fusion protein specific for cd137 and cd228
|